VivoSim Labs Business Summary

VivoSim Labs, INC. (VIVS), formerly known as Organovo Holdings, operates as a specialized biotechnology services provider focused on the commercialization of three-dimensional (3D) human tissue models for preclinical drug testing. The company generates revenue primarily through its NAMkind™ platform, which offers high-margin toxicology screening and research services for liver and intestinal tissues to pharmaceutical and biotechnology sponsors. Its business segments are bifurcated into preclinical safety testing services—utilizing proprietary NovoGen bioprinting and AI-driven multi-parametric toxicity signatures—and internal therapeutic development, notably the FXR314 candidate for inflammatory bowel disease. Positioned as a niche innovator in the New Approach Methodologies (NAM) market, VivoSim competes directly with small-cap peers such as Athira Pharma (LONA), Lixte Biotechnology (LIXT), and NanoViricides (NNVC), distinguishing itself through its focus on non-animal, human-relevant systems that mitigate late-stage clinical trial failures. The leadership team is anchored by Executive Chairman Keith Murphy, a serial entrepreneur who previously founded Organovo and held senior roles at Amgen, where he led global operations for denosumab. The executive suite was significantly bolstered in late 2025 and early 2026 with the appointments of Chief Scientific Officer Dr. Amar Sethi, a physician-scientist with 30 years of experience at Omeros and Pacific Biomarkers, and Chief Commercial Officer Tony Lialin, a veteran of Illumina and GRAIL. Financial oversight is managed by CFO Norman Staskey of Danforth Advisors, while Dr. Arumugham Raghunathan leads global sales as of March 2026. The company’s strategic direction is supported by a board including Lead Independent Director Douglas Jay Cohen and David Gobel, with notable insider ownership held by founders and early investors such as Keith Murphy and Gabor Forgacs.